A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

NCT04539938 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2 Positive Breast Cancer

Interventions

DRUG: tucatinib
DRUG: trastuzumab deruxtecan

Sponsor

Seagen, a wholly owned subsidiary of Pfizer